



PETER K. KAISER, MD
Medical Advisor, Retina Today;
Cole Eye Institute, Cleveland, OH

View Interactive
Version Online



If you would like to submit an addition for next year's poster, please email Peter K. Kaiser, MD, at pkkaiser@gmail.com and Cara Deming at cdeming@bmcctoday.com.

RT
Retina Today

RETINA PIPELINE 2026
A VIEW INTO ONGOING
INNOVATION **WET AMD**

Extracellular VEGF Pathways

- VEGF**
PIGF C/D B A
- pegaptanib (Bausch + Lomb) **FDA APPROVED**
 - Port Delivery System (Genentech/Roche) **FDA APPROVED**
 - ranibizumab (Genentech/Roche) **FDA APPROVED**
 - ranibizumab-nuna (Samsung/Biogen) **FDA APPROVED**
 - ranibizumab-eqrn (Sandoz) **FDA APPROVED**
 - ranibizumab-Ximluci (Xbrane Biopharma) **EMA APPROVED**
 - ranibizumab-Ranivisio (Teva) **EMA APPROVED**
 - ranibizumab-RanizuRel (Reliance Life Sciences) **INDIA FDA APPROVED**
 - ranibizumab-Razumab (Intas Pharmaceuticals) **INDIA FDA APPROVED**
 - ranibizumab-leyk (Formycon/Bioeq)
 - LUBT010 (Lupin Ltd/Amman)
 - SCT520FF (SinoCellTech)
 - SJP1-0133 (Senju Pharmaceutical)
 - BCD100 (BIOCND/Qilu)
 - CKD-701 (Chong Kun Dang)
 - biosimilars to ranibizumab
 - bevacizumab
 - bevacizumab-vikg (Outlook Therapeutics) **EMA/UK APPROVED**
 - TAB014 (Zhaoke Ophthalmology)
 - CT-P16 (Celltrion)
 - alymys (Amneal Pharmaceuticals/mAbxience)
 - EB12-20145P (EssexBio)
 - AK-3008 (Anhui Anke Biotechnology)
 - MIL-60 (Beijing Mabworks Biotech)
 - biosimilars to bevacizumab
 - brolocizumab (Novartis) **FDA APPROVED**
 - abicipar pegol (Molecular Partners)
 - KNP-301 (Kanaph Therapeutics)
 - tarcoicimab tedromer (Kodiak Sciences) **PIVOTAL STUDY**
 - VLTR-559 (Valitor) — Multivalent Polymer Conjugation
 - high-dose aflibercept (Regeneron) **FDA APPROVED**
 - aflibercept (Regeneron) **FDA APPROVED**
 - aflibercept-ayyh (Amgen) **FDA APPROVED**
 - aflibercept-jbvf (Biocan) **FDA APPROVED**
 - aflibercept-yszy (Samsung/Biogen) **FDA APPROVED**
 - aflibercept-abzv (Sandoz) **FDA APPROVED**
 - aflibercept-mrbb (Formycon) **FDA APPROVED**
 - aflibercept-boav (Celltrion) **FDA APPROVED**
 - ALT-L9 (Altas Biologics)
 - MYL-1701 (Mylan/Momenta)
 - RBS-001 (Rophibia)
 - SCD411 (Sam Chun Dang Pharmaceutical Co./Fresenius Kabi)
 - OT-702 (Ocumension Therapeutics/Shandong Boan)
 - AVT-06 (Alvotect)
 - conbercept (Kanghong Biotech) **CDE APPROVED**
 - IBI302 (Innovent Biologics) — Plus CR1 Inhibition
 - IBI333 (Innovent Biologics)
 - TH103 (Kalaris Therapeutics) — VEGFR1 domain3 + heparin-binding proteins
 - OPT-640 (OptigoBio)

Editorially independent content supported by advertising from Genentech

TIE2 Activation Pathways

- faricimab (Genentech/Roche) **FDA APPROVED**
- BI 836880 (Boehringer Ingelheim)
- VIS-101 (Visara)
- ABP-201 (AbPro)
- OLN324 (Ollin Biosciences)
- zifibancimig (Roche)
- RO-104 (RevOpsis)
- EB-105 (Eluminex Biosciences)
- AM-712 (AffaMed Therapeutics)
- PMC-403 (PharmAbcine) — TIE2 Activating MAB
- tiespectus (Merck/EyeBio) — TIE2 Activating bi-specific
- IGT-427 (Ingenia Therapeutics/Mosaic) — TIE2 Activating/anti-VEGF

Integrin Pathways

- PAN**
- risuteganib (Allegro/Affamed/Hanmi)
 - OCU200 (Ocugen) — Tumstatin and Transferrin Fusion Protein
 - AG-73305 (Allgenesis Biotherapeutics)
 - gersizangitide (AsclepiX Therapeutics)

Gene Therapy

- RGX-314 (Regenxbio/AbbVie) **PIVOTAL STUDY**
- AL-001 (Beijing Along Biopharmaceutical Co)
- HG202 (HuidaGene Therapeutics Co)
- ixoberogene soroparvovec (Adverum Biotechnologies) **PIVOTAL STUDY**
- NG101 (Neuraclle Genetics)
- LX102 (InnoStellar Biotherapeutics)
- E301 (Samsung)
- FT-003 (Frontera)
- ABI-t10 (Avirmax Biopharma)
- 4D-150 (4D Molecular Therapeutics) **PIVOTAL STUDY**
- EXG102-031 (Exegenesis Bio)
- KH631 (Kanghong Biotech)
- KH658 (Vanotech)
- HG202 (HuidaGene Therapeutics) — CRISPR/Cas13 RNA VEGF Editing
- BD311 (Shanghai BDgene Therapeutics Co)
- SKG0106 (Skyline Therapeutics)
- RRG001 (Refreshgene)
- IVB103 (InnoVec Biotherapeutics)
- PST-809 (PulseSight Therapeutics) — Non-Viral Anti-VEGF with Decorin Plasmid
- SAR402663 (Sanofi)
- AL-001 (Beijing Anlong Biopharmaceutical Co)
- CoTx-101 (Coave Therapeutics)

Other Pathways

- CVX-51401 (CavtheRx) — Caveolin Modulator
- EXN407 (Exonate/Janssen) — SRPK1 Inhibitor
- aganirsen (Gene Signal) — Inhibition of Insulin Receptor Substrate 1 (IRS-1)
- PL9654 (Palatin Technologies) — Melanocortin Receptor Agonist
- foselutoclast (Unity Biotechnology) — Bcl-xL Inhibitor
- EOM147 (EOM Pharmaceuticals) — Squalamine Analog
- ISTH0036 (Isarna Therapeutics) — TGF-Beta2 Antisense Oligonucleotide
- ATX-9874 (Augen/Duet Therapeutics) — Indoleamine 2,3-dioxygenase (IDO) Inhibitor
- CU06 (Curacle/Thea) — Block cAMP/Cortactin Pathway
- OLX-301D (OliX) — cp-asiRNA-CTGF/CCN2 Inhibitor
- umedaptanib pegol (Ribomic) — FGF2 Inhibitor
- RC28-E (RemeGen) — FGF2/VEGF Inhibitor **PIVOTAL STUDY**
- CG-P5 (Caregen) — CG-P5 Peptide
- OGX-110 (Ocugenix) — CXCR3 Chemokine Receptor 3 Agonist
- BBC1501 (BenoBio) — Targets BET (bromodomain and extra-terminal) Proteins
- ABF-101/103 (AptaBio) — Nox Inhibitor
- OCUL101 (Ocugen) — Anti-VEGF/C5

Interleukin Pathways



- KSI-501 (Kodiak Sciences) — Anti-VEGF/IL6 Antibody Polymer Conjugate (ABC) **PIVOTAL STUDY**
- KSI-101 (Kodiak Sciences) — Anti-IL6/VEGF
- SZN-8143 (Surrozen) — Anti-IL6/anti-VEGF/Fzd4 Agonist
- LNR-653.1 (Lanier Biotherapeutics) — Anti-IL17A/VEGF
- RO7497372 (Genentech) — Anti-IL6/VEGF

Tyrosine Kinase Inhibitors (TKI)

- Axpaxli/axitinib (Ocular Therapeutix) **PIVOTAL STUDY**
- AR-14034/axitinib (Alcon/Aerie)
- Duravyu/vorolanib (EyePoint Pharmaceuticals) **PIVOTAL STUDY**
- AIV007/lenvatinib (AiViva Biopharma)
- D-4517.2/migalidendrinib / sunitinib analog (Ashvattha Therapeutics)
- KPI-287 (Kala Pharmaceuticals)
- TO-0-1002 (TheratOcular Biotek Co., Ltd.)
- PAN 90806 (PanOptica)
- KHK4951/tivozanib (Kyowa Kirin Group)
- HX9428 (Fujian Haixi Pharmaceuticals)

WNT Pathways

- SYL-1801 (Sylentis) — siRNA Nrarp Inhibitor
- MK-3000 (EyeBio/Merck) — WNT Agonist
- SZN-413 (Surrozen) — Fzd4 Agonist
- SZN-8141 (Surrozen) — Fzd4 Agonist/Anti-VEGF



VABYSMO
faricimab-svoa injection 6 mg

IT'S NOT JUST DATA
IT'S REAL-WORLD RESULTS


DISCOVER HOW OUR REAL-WORLD DATA
MAKES A REAL DIFFERENCE



SCAN TO
EXPLORE FARETINA

Genentech
A Member of the Roche Group

**CHOOSE
VABYSMO®
FIRST**



1. Other Approaches

- OCU410 (Ocugen) – RORA (RAR-Related Orphan Receptor A) protein
- CT1812 (Cognition Therapeutics) – Selective α -2 Inhibition
- Xiflam (Inflamx/Bausch and Lomb) – Connexin 43 Inhibition
- Valeda Light Delivery System (LumiThera/Alcon) – Photobiomodulation **FDA Cleared**
- Xelafaslatide (ONL Therapeutics) – FAS Inhibition
- PST-611 (PulseSight Therapeutics) – DNA Plasmid Expressing Transferrin
- vutrisiran (Alnylam Pharmaceuticals) – siRNA TTR mRNA Inhibition
- FRX-001 (FerRx Bio) – Ferroptosis Inhibition
- BS01 (Bionic Sight) – ChronosFP Optogenetics
- BISC-109S (BISC Therapeutics) – Bax inhibitor
- i-Lumen (i-Lumen Scientific) – Microcurrent Stimulation **PIVOTAL STUDY**
- EG-301 (Evergreen Therapeutics)

2. Lipid Metabolism

- OSA-1-101 (Osanni Bio) – HMG-CoA Reductase Inhibition
- VGX-0111 (VisgenX) – ELOVL2 Gene Therapy
- BRX011 (Biojiva) – Deuterium-Stabilized DHA
- BI 1584862 (Boehringer Ingelheim) – Phospholipid Modulator
- CTX203 (CharacterBio) – apo-mimetic (L4F) peptide

3. Reduce Toxic By-Product Accumulation

Prevents Amyloid A β Oligomer Assembly

- GAL-101 (Galimedix Therapeutics/Thea)
- valiltramiprosate (Alzheon)

4. Neuroprotection

Repair Mitochondrial Dysfunction/Oxidative Stress

- elamipretide (Stealth Biotherapeutics) **PIVOTAL STUDY**
- risuteganib (Allegro/Affamed/Hanmi)
- OCLX-001 (Oculogenex) – Gene Therapy to Reduce Oxidative Stress

5. Visual Cycle Modulation

- gildeuretinol (Alkeus Pharmaceuticals) **PIVOTAL STUDY**
- tinlarebant (Belite Bio) **PIVOTAL STUDY**

6. Suppress Inflammation

Targeting the Complement Cascade

- 1 vonaprument (Annexon) – C1q Inhibition **PIVOTAL STUDY**
- 2 pegcetacoplan (Apellis/Biogen) – C3 Inhibition **FDA APPROVED**
- 3 CB-2782-PEG (Catalyst Biosciences) – C3 Protease
- 4 AMY106 (Amyndas Pharmaceuticals) – C3 Inhibition
- 5 SLN501 (Silence Therapeutics/Mallinckrodt Pharmaceuticals) – siRNA C3 mRNA Inhibition
- 6 ABBV-6628 (AbbVie) – C5 Inhibition
- 7 cemdisiran (Alnylam Pharmaceuticals) – siRNA C5 mRNA Inhibition
- 8 KNP-302 (Kanaph Therapeutics) – C3b and CD59 Inhibition
- 9 avacincaptad pegol (Astellas) – C5 Inhibition **FDA APPROVED**
- 10 ALXN1720 (Alexion) – C5 Inhibition
- 11 pozelimab/cemdisiran (Regeneron) – C5 Inhibition **PIVOTAL STUDY**
- 12 PASylated Nomacopan (Akari Therapeutics) – C5/LTB4 Inhibition
- 13 JNJ-1887 (Janssen) – sCD59 Gene Therapy
- 14 danicopan (Alexion Pharmaceuticals/AstraZeneca) – Complement Factor D Inhibition
- 15 BCX9930 (BioCryst Pharmaceuticals) – Complement Factor D Inhibition
- 16 sFH GTx (4DMT) – Complement Factor H Gene Therapy
- 17 CFH GTx (Syncona) – Complement Factor H Gene Therapy
- 18 AAV.sFH (Aevitas Therapeutics) – Short-Form Complement Factor H Gene Therapy
- 19 VOY-101 (Perceive Biotherapeutics) – Complement Factor H Gene Therapy
- 20 CB-4332 (Catalyst Biosciences) – Recombinant Complement Factor I
- 21 OMS721 (Omeros) – MASP-2 Inhibition
- 22 KNP-301 (Kanaph Therapeutics) – C3b/VEGF Inhibition
- 23 efdamrofusp alfa (Innovent Biologics) – sCR1/VEGF Inhibition
- 24 NM5072 (NovelMed) – Properdin Inhibition
- 25 KRIYA-825 (Kriya Therapeutics) – CR1/CR2 Gene Therapy
- 26 CTx001 (Complement Therapeutics) – CR1 Gene Therapy
- 27 iptacopan (Novartis) – Complement Factor B Inhibition
- 28 ADX-038 (ADARx) – Complement Factor B siRNA
- 29 SAR446597 (Sanofi) – Complement C1s and Bb Inhibitor
- 31 STL303 (Sitala Bio) – oral Complement Factor B inhibition

Macrophage Repolarization

- 30 AVD-104 (Aviceda Therapeutics) – Complement Factor H Activation
- TMi-018 (Translatum Medicus) – Blocks M1 Transcriptome Expression

Inflammasome Inhibition

- K8 (Inflammasome Therapeutics)

Matrix Modulation

- doxycycline (Galderma Labs)

7. Stem Cells

Human Embryonic Stem Cells (hESCs)

- OpRegen (Lineage Cell Therapeutics, Genentech/Roche)
- CPCB-RPE1 Implant (Regenerative Patch Technologies)
- ASP7317 (Astellas)
- Eyecyte-RPE (Eystem Research Ltd)
- RPESC-RPE-4W (Luxa Biotechnology)
- hESC RPE Sheets (Pfizer)
- HLS001 Cell Sheets (Sumitomo Dainippon Pharma)

Umbilical Stem Cells (hUTCs)

- Human Umbilical Stem Cells (iCyte)

